-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MlIB7nR2MbsTCW13bxnRebmb1/MAivYCqkEmKuJbM4KxuQJpz/le1UnJPUig3oaO 7MtYEc3B7Kul+QmYQrZg4g== 0001104659-10-003432.txt : 20100128 0001104659-10-003432.hdr.sgml : 20100128 20100128083102 ACCESSION NUMBER: 0001104659-10-003432 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100122 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20100128 DATE AS OF CHANGE: 20100128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 10552001 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQ CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 a10-2565_18k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 22, 2010

 

GENZYME CORPORATION

(Exact name of registrant as specified in its charter)

 

Massachusetts

 

0-14680

 

06-1047163

(State or other jurisdiction of
incorporation or organization)

 

(Commission file number)

 

(IRS employer identification
number)

 

500 Kendall Street, Cambridge, Massachusetts 02142

(Address of Principal Executive Offices)  (Zip Code)

 

Registrant’s telephone number, including area code: (617) 252-7500

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 22, 2010, the Compensation Committee (the “Committee”) of the Board of Directors of Genzyme Corporation (“Genzyme”) approved new designs for Genzyme’s annual cash incentive and long-term incentive programs for senior executives effective for 2010.

 

Annual Cash Incentive Program

 

The new senior executive annual cash incentive program, like the former one, is comprised of a corporate component and individual component for all senior executives, and a divisional component for senior executives with responsibilities for a business division.  As with the former program, the Committee plans to set a cash target incentive amount for each participant in December of each year.

 

Under the new senior executive annual cash incentive program, the performance metrics for the corporate component and the relative weighting of the components have changed.  The corporate metrics for 2010 are:  corporate revenue, cash flow return on invested capital (“CFROI”), and key business objectives. The key business objectives center on three areas, organization renewal, pipeline advancements, and recovery of the Personalized Genetic Health business.  The metric used to measure performance for the divisional component is division operating income.

 

For senior executives without a divisional component, the relative weight assigned to corporate metrics and individual performance is:

 

Revenue

 

40

%

CFROI

 

20

%

Key Business Objectives

 

20

%

Individual

 

20

%

 

For senior executives with division responsibility, the relative weight assigned to corporate and divisional metrics and individual performance is:

 

Revenue

 

35

%

CFROI

 

15

%

Key Business Objectives

 

15

%

Division Operating Income

 

15

%

Individual

 

20

%

 

At its meeting on January 22, 2010, the Committee approved the revenue, CFROI and division operating income performance targets for 2010.  The Committee approved performance and payout ranges for the revenue and CFROI metrics as follows:

 

Metric

 

Performance Range

 

Payout Range as a
Percent of Target
Award Opportunity

 

Revenue

 

90% to 115%

 

30% to 200%

 

CFROI

 

90% to 115%

 

50% to 200%

 

 

2


 

The payout range for divisional operating income was set at 50% to 180%, with the performance ranges set on a division-by-division basis.  The Committee also approved the objectives and criteria to be used to measure attainment of the key business objectives component of corporate performance.  As with the former annual cash incentive program, the individual component may be awarded based on the Committee’s review of the senior executive’s performance during the year.

 

Long Term Incentive Program

 

Genzyme’s new long-term incentive program for senior executives uses a combination of (i) time vesting stock options and (ii) performance vesting awards tied to the achievement of pre-established performance goals over a three-year performance period.  Approximately half the grant will be made in time vesting stock options with the remainder in performance vesting awards.  Grants under Genzyme’s former long-term incentive program were comprised of time vesting stock options and time vesting restricted stock units.

 

For the 2010-2012 performance period, the performance metrics are (i) relative total shareholder return (“TSR”) measured against the performance of a subset of biotechnology peer companies (currently twenty-eight organizations) in the S&P 500 Health Care index and (ii) CFROI.  Each metric is weighted equally.    For both metrics, performance between the threshold level and the target level will be awarded in performance vesting restricted stock units.  These units will be paid out in shares of Genzyme’s common stock at the end of the three-year period if performance between the threshold level and target level is achieved.  If performance above the target level is achieved, the portion of the award above the target level will be paid out in cash up to a predetermined maximum cash award.

 

At its meeting on January 22, 2010, the Committee approved a performance range for the three-year CFROI metric of 85% to 115%.  For performance between 85% and 100% of the CFROI target, the payout range is 50% to 100% of the senior executive’s target restricted stock unit award.  Performance between 101% and 115% of the CFROI target will result in a cash payment that will be awarded based on performance achieved between target and maximum levels, up to a predetermined maximum.  The Committee also approved the following performance levels for relative TSR:

 

Performance Level

 

Percentile Rank

Threshold

 

40th

Target

 

65th

Maximum

 

75th

 

For performance between the relative TSR threshold and target levels, the payout range is 35% to 100% of the senior executive’s target restricted stock unit award.  Relative TSR performance between the target and maximum levels will result in a cash payment that will be awarded based on performance achieved between target and maximum levels, up to a predetermined maximum.

 

3


 

If a participating senior executive’s employment is terminated before the end of the performance period because of death, disability or retirement, payment of the performance vesting award will be pro-rated to the date of termination based upon the company’s actual achievement of performance levels at the end of the performance period.  Upon a change in control, payment of a performance vesting award will be paid out at the target performance level and pro-rated to the date of the change of control.  The Committee has not yet granted any awards under the new long-term incentive program for senior executives.

 

4


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

GENZYME CORPORATION

 

 

 

 

 

Dated: January 28, 2010

By:

/s/ Peter Wirth

 

 

Peter Wirth

 

 

Executive Vice President, Legal and Corporate Development

 

5

 -----END PRIVACY-ENHANCED MESSAGE-----